915411-01-7

Basic information

• Product Name: 1H-INDAZOL-7-YL BORONIC ACID
• Synonyms: 1H-INDAZOL-7-YL BORONIC ACID;1H-Indazole-7-boronic acid;1H-indazol-7-yl-7-boronic acid;7-Borono-1H-indazole;boronic acid of 7-bromoindazole
• CAS NO: 915411-01-7
• Molecular Formula: C₇H₇BN₂O₂
• Molecular Weight: 151.0
• Product Categories: Indazole;Organoborons
• Mol File: 915411-01-7.mol

Chemical Properties

• Boiling Point: 457 °C at 760 mmHg
• Flash Point: 230.2 °C
• Appearance: /
• Density: 1.42 g/cm³
• Vapor Pressure: 3.81E-09mmHg at 25°C
• Refractive Index: 1.671
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.37±0.30(Predicted)
• CAS DataBase Reference: 1H-INDAZOL-7-YL BORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-INDAZOL-7-YL BORONIC ACID(915411-01-7)
• EPA Substance Registry System: 1H-INDAZOL-7-YL BORONIC ACID(915411-01-7)

Safety Data

• Hazardous Substances Data: 915411-01-7(Hazardous Substances Data)

Usage

Uses

1H-Indazol-7-ylboronic acid

InChI:InChI=1/C7H7BN2O2/c11-8(12)6-3-1-2-5-4-9-10-7(5)6/h1-4,11-12H,(H,9,10)

Upstream product

• 915411-02-8 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 21443-96-9 1H-indazol-7-amine 
• 2942-42-9 7-Nitroindazole 
• 53857-58-2 7-bromo-1H-indazole 

Relevant articles and documents

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

ANTI-CANCER AGENTS ANS USES THEREOF

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.